Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Artery Disease | 14 | 2017 | 878 | 1.240 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 3 | 2017 | 25 | 0.670 |
Why?
|
| Cardiovascular Diseases | 10 | 2021 | 2099 | 0.640 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2017 | 39 | 0.520 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2017 | 72 | 0.520 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 450 | 0.500 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 228 | 0.390 |
Why?
|
| Carcinoid Heart Disease | 1 | 2012 | 2 | 0.360 |
Why?
|
| Coronary Vasospasm | 1 | 2012 | 12 | 0.360 |
Why?
|
| Allylamine | 1 | 2011 | 8 | 0.360 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 24 | 0.350 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 84 | 0.330 |
Why?
|
| Metabolic Syndrome | 2 | 2016 | 366 | 0.330 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 3053 | 0.320 |
Why?
|
| Exercise | 4 | 2023 | 866 | 0.310 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 234 | 0.290 |
Why?
|
| Biomarkers | 9 | 2017 | 3397 | 0.290 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 241 | 0.290 |
Why?
|
| Coronary Angiography | 6 | 2017 | 457 | 0.260 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 539 | 0.250 |
Why?
|
| Oxidative Stress | 3 | 2016 | 804 | 0.240 |
Why?
|
| Vascular Stiffness | 2 | 2017 | 82 | 0.230 |
Why?
|
| Risk Factors | 18 | 2017 | 10993 | 0.230 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2306 | 0.220 |
Why?
|
| Risk Assessment | 7 | 2017 | 3712 | 0.190 |
Why?
|
| Athletes | 1 | 2023 | 72 | 0.190 |
Why?
|
| Vasodilator Agents | 2 | 2014 | 201 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2016 | 637 | 0.170 |
Why?
|
| Aged | 15 | 2017 | 20925 | 0.160 |
Why?
|
| Patient Care | 1 | 2021 | 97 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2015 | 5085 | 0.160 |
Why?
|
| Myocardial Infarction | 4 | 2017 | 998 | 0.160 |
Why?
|
| Male | 23 | 2023 | 64557 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 1410 | 0.140 |
Why?
|
| Humans | 34 | 2023 | 130574 | 0.140 |
Why?
|
| Risk Reduction Behavior | 2 | 2016 | 149 | 0.140 |
Why?
|
| Death | 2 | 2016 | 78 | 0.140 |
Why?
|
| Middle Aged | 16 | 2017 | 28448 | 0.140 |
Why?
|
| Air Travel | 1 | 2017 | 2 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 1298 | 0.130 |
Why?
|
| Obesity, Abdominal | 1 | 2017 | 41 | 0.130 |
Why?
|
| Aerospace Medicine | 1 | 2017 | 37 | 0.130 |
Why?
|
| Electrocardiography | 2 | 2013 | 981 | 0.130 |
Why?
|
| Female | 20 | 2017 | 70509 | 0.120 |
Why?
|
| Arteries | 1 | 2017 | 208 | 0.120 |
Why?
|
| Angina, Stable | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cardiac Rehabilitation | 1 | 2016 | 29 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2017 | 100 | 0.120 |
Why?
|
| Vasodilation | 1 | 2017 | 175 | 0.120 |
Why?
|
| Cardiology | 2 | 2021 | 511 | 0.120 |
Why?
|
| Fibrin | 1 | 2016 | 64 | 0.120 |
Why?
|
| Biological Products | 1 | 2018 | 144 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 272 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 101 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2016 | 165 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2016 | 199 | 0.110 |
Why?
|
| Microvessels | 1 | 2015 | 61 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 34 | 0.110 |
Why?
|
| Solubility | 1 | 2014 | 117 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2016 | 219 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 97 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2016 | 177 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 513 | 0.110 |
Why?
|
| Rubidium Radioisotopes | 1 | 2014 | 3 | 0.110 |
Why?
|
| Microcirculation | 1 | 2014 | 106 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 149 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2016 | 171 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 208 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2017 | 466 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2023 | 1342 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 475 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2014 | 192 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 383 | 0.100 |
Why?
|
| Coronary Aneurysm | 1 | 2013 | 34 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5221 | 0.090 |
Why?
|
| Survival Rate | 2 | 2014 | 2136 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 748 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 186 | 0.090 |
Why?
|
| Apolipoproteins A | 1 | 2012 | 52 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2121 | 0.090 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2012 | 28 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2014 | 395 | 0.090 |
Why?
|
| Octreotide | 1 | 2012 | 24 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 292 | 0.090 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2011 | 5 | 0.090 |
Why?
|
| Age of Onset | 2 | 2012 | 596 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2014 | 533 | 0.090 |
Why?
|
| Proteomics | 1 | 2015 | 606 | 0.090 |
Why?
|
| Cholesterol, LDL | 2 | 2012 | 615 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 696 | 0.080 |
Why?
|
| Adult | 9 | 2017 | 31202 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 110 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2011 | 79 | 0.080 |
Why?
|
| Fluorobenzenes | 1 | 2011 | 39 | 0.080 |
Why?
|
| Heart Rate | 1 | 2014 | 577 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 226 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 442 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 252 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 895 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 711 | 0.080 |
Why?
|
| Testosterone | 1 | 2015 | 590 | 0.080 |
Why?
|
| Asia | 1 | 2009 | 125 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2014 | 12891 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 346 | 0.070 |
Why?
|
| Inflammation | 2 | 2014 | 1489 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2009 | 122 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2011 | 295 | 0.070 |
Why?
|
| Cholesterol | 1 | 2011 | 540 | 0.070 |
Why?
|
| Lipids | 1 | 2012 | 564 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2011 | 246 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2011 | 450 | 0.070 |
Why?
|
| Cardiac Catheterization | 1 | 2012 | 634 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 1594 | 0.060 |
Why?
|
| Prevalence | 2 | 2014 | 2683 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 901 | 0.060 |
Why?
|
| Prognosis | 4 | 2017 | 4927 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 2849 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 6773 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2009 | 276 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 456 | 0.060 |
Why?
|
| Stents | 1 | 2012 | 783 | 0.060 |
Why?
|
| Glutathione Disulfide | 2 | 2015 | 20 | 0.060 |
Why?
|
| Cystine | 2 | 2015 | 14 | 0.060 |
Why?
|
| Depression | 1 | 2014 | 1318 | 0.060 |
Why?
|
| Obesity | 1 | 2016 | 2389 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 1558 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2012 | 949 | 0.050 |
Why?
|
| Cysteine | 2 | 2015 | 137 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1841 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 703 | 0.050 |
Why?
|
| Glutathione | 2 | 2015 | 199 | 0.050 |
Why?
|
| Physical Endurance | 1 | 2023 | 42 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 905 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 67 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 783 | 0.050 |
Why?
|
| Linear Models | 2 | 2014 | 690 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2021 | 43 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 1684 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2015 | 6475 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 161 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 1124 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 2844 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2014 | 1509 | 0.040 |
Why?
|
| Pregnancy | 1 | 2011 | 7492 | 0.040 |
Why?
|
| Echocardiography | 2 | 2014 | 1135 | 0.030 |
Why?
|
| Work Capacity Evaluation | 1 | 2017 | 3 | 0.030 |
Why?
|
| Atmospheric Pressure | 1 | 2017 | 5 | 0.030 |
Why?
|
| Pilots | 1 | 2017 | 3 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2017 | 32 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 53 | 0.030 |
Why?
|
| Aircraft | 1 | 2017 | 21 | 0.030 |
Why?
|
| Occupational Health | 1 | 2017 | 47 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 198 | 0.030 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 19 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 194 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2932 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 194 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 766 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 94 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 734 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 240 | 0.030 |
Why?
|
| Immune System | 1 | 2014 | 98 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 321 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 207 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 423 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 164 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 102 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 332 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 240 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2016 | 468 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 225 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 324 | 0.020 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2012 | 79 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 187 | 0.020 |
Why?
|
| Aminohydrolases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Formate-Tetrahydrofolate Ligase | 1 | 2011 | 4 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2014 | 185 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2011 | 7 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 2012 | 83 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2011 | 76 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 527 | 0.020 |
Why?
|
| Rosuvastatin Calcium | 1 | 2011 | 42 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 517 | 0.020 |
Why?
|
| Diet | 1 | 2018 | 1115 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9991 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1143 | 0.020 |
Why?
|
| Global Health | 1 | 2015 | 624 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2014 | 809 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1387 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2201 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 394 | 0.020 |
Why?
|
| Heart Atria | 1 | 2013 | 335 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1336 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2012 | 194 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2012 | 260 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 183 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1228 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 449 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2013 | 527 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 742 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 318 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 1017 | 0.020 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 369 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1814 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 1932 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 642 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 3344 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 1246 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 6223 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3816 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 2609 | 0.010 |
Why?
|
| Stroke | 1 | 2012 | 1041 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 4034 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3413 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3844 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11820 | 0.010 |
Why?
|
| Animals | 1 | 2018 | 33899 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 20774 | 0.010 |
Why?
|